Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.
暂无分享,去创建一个
Philip T Sager | Steven R Houser | S. Houser | P. Sager | Joseph C. Wu | Joseph C Wu | Yingxin Li | K. Sallam | Karim Sallam | Yingxin Li | Karim Sallam
[1] Joseph C. Wu,et al. Patient-specific stem cells and cardiovascular drug discovery. , 2013, JAMA.
[2] R. Guy,et al. International Conference on Harmonisation , 2014 .
[3] S. Houser,et al. Enhanced basal contractility but reduced excitation-contraction coupling efficiency and beta-adrenergic reserve of hearts with increased Cav1.2 activity. , 2010, American journal of physiology. Heart and circulatory physiology.
[4] T. Okano,et al. Composite Cell Sheets: A Further Step Toward Safe and Effective Myocardial Regeneration by Cardiac Progenitors Derived From Embryonic Stem Cells , 2010, Circulation.
[5] S. Szeinbach,et al. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 , 2011, Pharmacoepidemiology and drug safety.
[6] A. Krahn,et al. Contemporary Reviews in Cardiovascular Medicine Sudden Cardiac Arrest Without Overt Heart Disease , 2011 .
[7] Michael Glikson,et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. , 2012, Journal of the American College of Cardiology.
[8] Chad H. Koonce,et al. Stem Cells and Their Derivatives: A Renaissance in Cardiovascular Translational Research , 2011, Journal of cardiovascular translational research.
[9] Dan M Roden,et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. , 2012, Journal of the American College of Cardiology.
[10] International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. , 2005, Federal register.
[11] A. Camm,et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.
[12] W. McKenna,et al. Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment , 2013, Canadian Medical Association Journal.
[13] Mark R Bowlby,et al. Development of a Novel Automated Ion Channel Recording Method Using “Inside-Out” Whole-Cell Membranes , 2005, Journal of biomolecular screening.
[14] Erik Willems,et al. Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery , 2013, Circulation research.
[15] Hung-Fat Tse,et al. Electrical Stimulation Promotes Maturation of Cardiomyocytes Derived from Human Embryonic Stem Cells , 2013, Journal of Cardiovascular Translational Research.
[16] G. Dorn,et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. , 2003, The Journal of clinical investigation.
[17] Euan A. Ashley,et al. Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.
[18] Paul B Bennett,et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. , 2003, Assay and drug development technologies.
[19] H. Calkins,et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.
[20] P. Coumel,et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.
[21] F. Spinale,et al. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. , 2009, Circulation. Heart failure.
[22] Wataru Shimizu,et al. Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.
[23] Tomoaki Inoue,et al. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. , 2011, Journal of pharmacological sciences.
[24] U. Frey,et al. Microelectronic system for high-resolution mapping of extracellular electric fields applied to brain slices. , 2009, Biosensors & bioelectronics.
[25] Lawrence Buja,et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. , 2008, Journal of molecular and cellular cardiology.
[26] Jonathan A. Bernstein,et al. Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.
[27] P. Podrid. Proarrhythmia, a serious complication of antiarrhythmic drugs , 1999, Current cardiology reports.
[28] Michael George,et al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. , 2009, Combinatorial chemistry & high throughput screening.
[29] Teng Hong Tan,et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. , 2013, International journal of cardiology.
[30] D. Roden. Repolarization reserve: a moving target. , 2008, Circulation.
[31] D. Corrado,et al. Pros and cons of screening for sudden cardiac death in sports , 2013, Heart.
[32] R. Dolmetsch,et al. Modeling Timothy Syndrome with iPS Cells , 2013, Journal of Cardiovascular Translational Research.
[33] Donald M Bers,et al. Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.
[34] 江頭 徹. Disease characterization using LQTS-specific induced pluripotent stem cells , 2013 .
[35] S. Kattman,et al. The generation of the epicardial lineage from human pluripotent stem cells , 2014, Nature Biotechnology.
[36] H. R. Lu,et al. Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. , 2013, Stem Cell Research.
[37] A. Brown,et al. A history of the role of the hERG channel in cardiac risk assessment. , 2013, Journal of pharmacological and toxicological methods.
[38] Niels Voigt,et al. Cardiac safety assays. , 2014, Current opinion in pharmacology.
[39] Marylyn D. Ritchie,et al. A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes , 2012, Circulation. Cardiovascular genetics.
[40] Michael J Ackerman,et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[41] P. Sager,et al. Electrocardiographic assessment for therapeutic proteins--scientific discussion. , 2010, American heart journal.
[42] N. McMahon,et al. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[43] Dan M. Roden,et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .
[44] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[45] S. Houser,et al. Cardiac G-Protein–Coupled Receptor Kinase 2 Ablation Induces a Novel Ca2+ Handling Phenotype Resistant to Adverse Alterations and Remodeling After Myocardial Infarction , 2012, Circulation.
[46] Philip Wong,et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.
[47] C. Murry,et al. Cardiac regeneration using pluripotent stem cells--progression to large animal models. , 2014, Stem cell research.
[48] J. Dunlop,et al. A novel method for patch-clamp automation , 2006, Pflügers Archiv.
[49] Gary R. Mirams,et al. Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials , 2013, British journal of pharmacology.
[50] Robert Passier,et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. , 2010, Stem cell research.
[51] M. Viitasalo,et al. Evaluation of QT interval duration and dispersion and proposed clinical criteria in diagnosis of long QT syndrome in patients with a genetically uniform type of LQT1. , 1998, Journal of the American College of Cardiology.
[52] Barry J Maron,et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardi , 2008, Journal of the American College of Cardiology.
[53] Stanley Nattel,et al. Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs , 2013, The Journal of physiology.
[54] Robert W. Mills,et al. Rapid Cellular Phenotyping of Human Pluripotent Stem Cell-Derived Cardiomyocytes using a Genetically Encoded Fluorescent Voltage Sensor , 2014, Stem cell reports.
[55] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[56] J. Healey,et al. Systematic Assessment of Patients With Unexplained Cardiac Arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) , 2009, Circulation.
[57] Andrew J. Sauer,et al. Contemporary Reviews in Cardiovascular Medicine Clinical and Genetic Determinants of Torsade de Pointes Risk , 2012 .
[58] Joseph C. Wu,et al. Induced pluripotent stem cells. , 2015, JAMA.
[59] G K Isbister,et al. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. , 2007, QJM : monthly journal of the Association of Physicians.
[60] Azra Fatima,et al. In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.
[61] Donald M Bers,et al. Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.
[62] José Jalife,et al. Optical Imaging of Voltage and Calcium in Cardiac Cells & Tissues , 2012, Circulation research.
[63] G. Keller,et al. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. , 2014, Biomaterials.
[64] J. Brugada,et al. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.
[65] S. Yamanaka,et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.
[66] P. Burridge,et al. A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards , 2013, Journal of Cardiovascular Translational Research.
[67] P. Kirchhof,et al. Familial Hypertrophic Cardiomyopathy-Linked Mutant Troponin T Causes Stress-Induced Ventricular Tachycardia and Ca2+-Dependent Action Potential Remodeling , 2003, Circulation research.
[68] R. Papke,et al. Estimation of both the potency and efficacy of alpha7 nAChR agonists from single-concentration responses. , 2006, Life sciences.
[69] J. Itskovitz‐Eldor,et al. Differences between human and mouse embryonic stem cells. , 2004, Developmental biology.
[70] E. Lander,et al. Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .
[71] Ofer Binah,et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.
[72] Mathias Jucker,et al. The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.
[73] Lior Gepstein,et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. , 2009, Stem cells and development.
[74] Thomas O'Hara,et al. Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. , 2012, American journal of physiology. Heart and circulatory physiology.
[75] R. Nagai,et al. The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization. , 1997, European heart journal.
[76] Gordon Keller,et al. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. , 2012, Cell stem cell.
[77] L. Bailey,et al. Isolation, Characterization, and Spatial Distribution of Cardiac Progenitor Cells in the Sheep Heart. , 2012, Journal of clinical & experimental cardiology.
[78] P. Sager,et al. Moving towards better predictors of drug‐induced torsades de pointes , 2008, British journal of pharmacology.
[79] L. Rochette,et al. Postnatal Overfeeding Causes Early Shifts in Gene Expression in the Heart and Long-Term Alterations in Cardiometabolic and Oxidative Parameters , 2013, PloS one.
[80] H. Calkins,et al. Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy , 2014, Science Translational Medicine.
[81] Arthur A M Wilde,et al. Cardiac ion channels in health and disease. , 2010, Heart rhythm.
[82] James A Thomson,et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.
[83] Y Rudy,et al. Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death. , 2001, Cardiovascular research.
[84] F. Acocella,et al. Large animal models for cardiac stem cell therapies. , 2011, Theriogenology.
[85] H. Mistry,et al. An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment. , 2012, American journal of physiology. Heart and circulatory physiology.
[86] John Sharkey,et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.
[87] H. Jneid,et al. Intracoronary Delivery of Autologous Cardiac Stem Cells Improves Cardiac Function in a Porcine Model of Chronic Ischemic Cardiomyopathy , 2013, Circulation.
[88] Raatikainen Mj,et al. New antiarrhythmic drugs for treatment of atrial fibrillation , 2010 .
[89] Laura Iop,et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia , 2012, EMBO molecular medicine.
[90] Lior Gepstein,et al. Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.
[91] S. Chugh,et al. Sudden cardiac death with apparently normal heart. , 2000, Circulation.
[92] Paul W. Burridge,et al. Human Stem Cells for Modeling Heart Disease and for Drug Discovery , 2014, Science Translational Medicine.
[93] L. Eckardt,et al. A prospective study on spontaneous fluctuations between diagnostic and non-diagnostic ECGs in Brugada syndrome: implications for correct phenotyping and risk stratification. , 2006, European heart journal.
[94] Y. Li,et al. β-Adrenergic Stimulation Increases Cav3.1 Activity in Cardiac Myocytes through Protein Kinase A , 2012, PloS one.
[95] Gary R. Mirams,et al. Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk , 2011, Cardiovascular research.
[96] R. Shah,et al. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. , 2005, Novartis Foundation symposium.
[97] Shinya Yamanaka,et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. , 2013, Circulation journal : official journal of the Japanese Circulation Society.
[98] N. Nakatsuji,et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. , 2013, European heart journal.
[99] B. Doble,et al. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. , 2010, The Journal of clinical investigation.
[100] Katriina Aalto-Setälä,et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture , 2011, Disease Models & Mechanisms.
[101] Clemens Möller,et al. Automated planar patch-clamp. , 2013, Methods in molecular biology.
[102] Karl-Ludwig Laugwitz,et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, The New England journal of medicine.
[103] A. Wilde,et al. SCN5A overlap syndromes: no end to disease complexity? , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[104] Kapil Kumar,et al. Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[105] N. Weissman,et al. Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin , 2000, The Journal of physiology.
[106] A. Jervell,et al. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval, and sudden death , 1957 .
[107] Euan A Ashley,et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.
[108] D. Dobrev,et al. New directions in antiarrhythmic drug therapy for atrial fibrillation. , 2013, Future cardiology.
[109] Jürgen Hescheler,et al. Organotypic slice culture from human adult ventricular myocardium. , 2012, Cardiovascular research.
[110] Michael Fejtl,et al. The roboocyte: automated cDNA/mRNA injection and subsequent TEVC recording on Xenopus oocytes in 96-well microtiter plates. , 2003, Receptors & channels.
[111] T. Smart,et al. HEK293 cell line: a vehicle for the expression of recombinant proteins. , 2005, Journal of pharmacological and toxicological methods.
[112] Divya Rajamohan,et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European Heart Journal.
[113] M. Kay,et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. , 2014, Journal of the American College of Cardiology.
[114] C. Tracy,et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.
[115] C. Mummery,et al. Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. , 2011, Trends in molecular medicine.
[116] Lei Yang,et al. Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.
[117] P Ducimetière,et al. Predicting sudden death in the population: the Paris Prospective Study I. , 1999, Circulation.
[118] D. Dobrev,et al. Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. , 2005, The Journal of thoracic and cardiovascular surgery.
[119] Feng Chen,et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. , 2014, Cell stem cell.
[120] Ferran Sanz,et al. A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity , 2011, J. Chem. Inf. Model..
[121] International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. , 2005, Federal register.
[122] Gary Gintant,et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. , 2014, American heart journal.
[123] J J Heger,et al. Sudden cardiac death. , 1998, Circulation.
[124] A. Sandoval,et al. Whole-cell patch-clamp recording of recombinant voltage-sensitive Ca2+ channels heterologously expressed in HEK-293 cells. , 2014, Cold Spring Harbor protocols.
[125] Udo Kraushaar,et al. Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals , 2010, Expert opinion on drug metabolism & toxicology.
[126] M. Spira,et al. Multi-electrode array technologies for neuroscience and cardiology. , 2013, Nature nanotechnology.
[127] C. Mummery,et al. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias , 2012, Front. Physio..
[128] C. Mummery,et al. Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease , 2012, Circulation.
[129] D. Roden. Long QT syndrome: reduced repolarization reserve and the genetic link , 2006, Journal of internal medicine.
[130] Gene Kim,et al. MicroRNA regulation of cardiac conduction and arrhythmias. , 2013, Translational research : the journal of laboratory and clinical medicine.
[131] Stanley Nattel,et al. Molecular basis of species-specific expression of repolarizing K+ currents in the heart. , 2003, American journal of physiology. Heart and circulatory physiology.
[132] S. Schiffmann,et al. Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia , 2012, Disease Models & Mechanisms.
[133] E. Behr,et al. Drug-induced arrhythmia: pharmacogenomic prescribing? , 2013, European heart journal.
[134] O. Abilez,et al. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. , 2014, Journal of the American College of Cardiology.
[135] Xu Xiaoping,et al. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype. , 2013, American journal of physiology. Heart and circulatory physiology.